[
  {
    "ts": null,
    "headline": "Viatris Inc. stock rises Thursday, outperforms market",
    "summary": "Viatris Inc. stock rises Thursday, outperforms market",
    "url": "https://finnhub.io/api/news?id=fc03add4819ec335274efe1eb8044ba83cf962037d45813286fe84446142958e",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746724740,
      "headline": "Viatris Inc. stock rises Thursday, outperforms market",
      "id": 134358026,
      "image": "",
      "related": "VTRS",
      "source": "MarketWatch",
      "summary": "Viatris Inc. stock rises Thursday, outperforms market",
      "url": "https://finnhub.io/api/news?id=fc03add4819ec335274efe1eb8044ba83cf962037d45813286fe84446142958e"
    }
  },
  {
    "ts": null,
    "headline": "Viatris Q1 Earnings and Revenues Beat Estimates, Stock Gains",
    "summary": "VTRS Q1 earnings and sales beat estimates. Brands business continues to perform well backed by expansion of portfolio.",
    "url": "https://finnhub.io/api/news?id=a1797fa84d96930a9b4bb06c542e0997adc88262c024ec40320eecdd379d28cf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746722280,
      "headline": "Viatris Q1 Earnings and Revenues Beat Estimates, Stock Gains",
      "id": 134336369,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VTRS",
      "source": "Yahoo",
      "summary": "VTRS Q1 earnings and sales beat estimates. Brands business continues to perform well backed by expansion of portfolio.",
      "url": "https://finnhub.io/api/news?id=a1797fa84d96930a9b4bb06c542e0997adc88262c024ec40320eecdd379d28cf"
    }
  },
  {
    "ts": null,
    "headline": "Viatris (NASDAQ:VTRS) Reports Sales Below Analyst Estimates In Q1 Earnings, But Stock Soars 8%",
    "summary": "Medication company Viatris (NASDAQ:VTRS) fell short of the market’s revenue expectations in Q1 CY2025, with sales falling 11.2% year on year to $3.25 billion. The company’s full-year revenue guidance of $13.75 billion at the midpoint came in 0.5% below analysts’ estimates. Its non-GAAP profit of $0.50 per share was in line with analysts’ consensus estimates.",
    "url": "https://finnhub.io/api/news?id=53442cf125761a8eb28b2ba7cb024e46948c00666047b8f430387aa8af4cd9ea",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746712480,
      "headline": "Viatris (NASDAQ:VTRS) Reports Sales Below Analyst Estimates In Q1 Earnings, But Stock Soars 8%",
      "id": 134325654,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VTRS",
      "source": "Yahoo",
      "summary": "Medication company Viatris (NASDAQ:VTRS) fell short of the market’s revenue expectations in Q1 CY2025, with sales falling 11.2% year on year to $3.25 billion. The company’s full-year revenue guidance of $13.75 billion at the midpoint came in 0.5% below analysts’ estimates. Its non-GAAP profit of $0.50 per share was in line with analysts’ consensus estimates.",
      "url": "https://finnhub.io/api/news?id=53442cf125761a8eb28b2ba7cb024e46948c00666047b8f430387aa8af4cd9ea"
    }
  },
  {
    "ts": null,
    "headline": "Viatris (VTRS) Reports Q1 Earnings: What Key Metrics Have to Say",
    "summary": "While the top- and bottom-line numbers for Viatris (VTRS) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.",
    "url": "https://finnhub.io/api/news?id=25355a23f047b8536f4e8ccc0c0898eb4c6503fd48fb4017f3fb20bffa1bdaa5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746711030,
      "headline": "Viatris (VTRS) Reports Q1 Earnings: What Key Metrics Have to Say",
      "id": 134325655,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VTRS",
      "source": "Yahoo",
      "summary": "While the top- and bottom-line numbers for Viatris (VTRS) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.",
      "url": "https://finnhub.io/api/news?id=25355a23f047b8536f4e8ccc0c0898eb4c6503fd48fb4017f3fb20bffa1bdaa5"
    }
  },
  {
    "ts": null,
    "headline": "Viatris Q1 Earnings Review: Shares Are Up, Time To Sell (Rating Downgrade)",
    "summary": "Viatris faces tariff pressures, FDA concerns, and geopolitical risks despite some pipeline promise and stable guidance. Read why VTRS stock is a sell.",
    "url": "https://finnhub.io/api/news?id=7ea182c6ab58c0bbf4150c7273d0804d82be7a00770ef9d7fd3d2e6d4df99a31",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746708069,
      "headline": "Viatris Q1 Earnings Review: Shares Are Up, Time To Sell (Rating Downgrade)",
      "id": 134327351,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/104271845/image_104271845.jpg?io=getty-c-w1536",
      "related": "VTRS",
      "source": "SeekingAlpha",
      "summary": "Viatris faces tariff pressures, FDA concerns, and geopolitical risks despite some pipeline promise and stable guidance. Read why VTRS stock is a sell.",
      "url": "https://finnhub.io/api/news?id=7ea182c6ab58c0bbf4150c7273d0804d82be7a00770ef9d7fd3d2e6d4df99a31"
    }
  },
  {
    "ts": null,
    "headline": "Viatris (VTRS) Beats Q1 Earnings and Revenue Estimates",
    "summary": "Viatris (VTRS) delivered earnings and revenue surprises of 2.04% and 0.81%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?",
    "url": "https://finnhub.io/api/news?id=23891c0ea9a981d543051e795b4e8c97e6ec038e77039877b3d32772a11038e6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746706512,
      "headline": "Viatris (VTRS) Beats Q1 Earnings and Revenue Estimates",
      "id": 134325656,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VTRS",
      "source": "Yahoo",
      "summary": "Viatris (VTRS) delivered earnings and revenue surprises of 2.04% and 0.81%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?",
      "url": "https://finnhub.io/api/news?id=23891c0ea9a981d543051e795b4e8c97e6ec038e77039877b3d32772a11038e6"
    }
  },
  {
    "ts": null,
    "headline": "Viatris: Q1 Earnings Snapshot",
    "summary": "CANONSBURG, Pa. AP) — Viatris Inc (VTRS) on Thursday reported a loss of $3.04 billion in its first quarter. On a per-share basis, the Canonsburg, Pennsylvania-based company said it had a loss of $2.55.",
    "url": "https://finnhub.io/api/news?id=3ce814fc80f8c53814cc777795ca74b5e6f3607b575c31a0566203b9e5a0caf9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746702631,
      "headline": "Viatris: Q1 Earnings Snapshot",
      "id": 134325657,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VTRS",
      "source": "Yahoo",
      "summary": "CANONSBURG, Pa. AP) — Viatris Inc (VTRS) on Thursday reported a loss of $3.04 billion in its first quarter. On a per-share basis, the Canonsburg, Pennsylvania-based company said it had a loss of $2.55.",
      "url": "https://finnhub.io/api/news?id=3ce814fc80f8c53814cc777795ca74b5e6f3607b575c31a0566203b9e5a0caf9"
    }
  },
  {
    "ts": null,
    "headline": "Viatris Reports First Quarter 2025 Results and Reaffirms 2025 Outlook",
    "summary": "Viatris Inc. (Nasdaq: VTRS) today reported first quarter 2025 financial results and reaffirmed its 2025 outlook[1].",
    "url": "https://finnhub.io/api/news?id=f0e59ba979f01f362e9b842c0944404aabfa8416753fa2293aefb8e5bd5168c3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746701940,
      "headline": "Viatris Reports First Quarter 2025 Results and Reaffirms 2025 Outlook",
      "id": 134325658,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VTRS",
      "source": "Yahoo",
      "summary": "Viatris Inc. (Nasdaq: VTRS) today reported first quarter 2025 financial results and reaffirmed its 2025 outlook[1].",
      "url": "https://finnhub.io/api/news?id=f0e59ba979f01f362e9b842c0944404aabfa8416753fa2293aefb8e5bd5168c3"
    }
  },
  {
    "ts": null,
    "headline": "Viatris Announces Positive Results from Phase 3 Study of Investigational XULANE LO™ Low Dose Patch for Birth Control in Women of Childbearing Potential",
    "summary": "Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced positive results of its Phase 3 study (NCT05139121) evaluating the contraceptive efficacy and safety of investigational XULANE LO low dose weekly dermal patch of 150 mcg norelgestromin and 17.5 mcg ethinyl estradiol per day in women of childbearing potential. The study evaluated women of childbearing potential (N=1,272) for up to 13 cycles (12,591 safety evaluable cycles and 9,105 efficacy evaluable cycles) across 81 inves",
    "url": "https://finnhub.io/api/news?id=03ad468694088f4fbb4d9b4e1d7bb84ec4135ed0ad77c8a260fcfca444ab2f36",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746701100,
      "headline": "Viatris Announces Positive Results from Phase 3 Study of Investigational XULANE LO™ Low Dose Patch for Birth Control in Women of Childbearing Potential",
      "id": 134325659,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VTRS",
      "source": "Yahoo",
      "summary": "Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced positive results of its Phase 3 study (NCT05139121) evaluating the contraceptive efficacy and safety of investigational XULANE LO low dose weekly dermal patch of 150 mcg norelgestromin and 17.5 mcg ethinyl estradiol per day in women of childbearing potential. The study evaluated women of childbearing potential (N=1,272) for up to 13 cycles (12,591 safety evaluable cycles and 9,105 efficacy evaluable cycles) across 81 inves",
      "url": "https://finnhub.io/api/news?id=03ad468694088f4fbb4d9b4e1d7bb84ec4135ed0ad77c8a260fcfca444ab2f36"
    }
  },
  {
    "ts": null,
    "headline": "Viatris Inc. (VTRS) Q1 2025 Earnings Call Transcript",
    "summary": "Viatris Inc. (NASDAQ:VTRS) Q1 2025 Earnings Conference Call May 8, 2025 8:30 AM ETCompany ParticipantsBill Szablewski - Head of Capital MarketsScott Smith -...",
    "url": "https://finnhub.io/api/news?id=55259bb63b342c62860292110a494b186b9bb506f91a6992fc3d67840ce8d4c8",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746700536,
      "headline": "Viatris Inc. (VTRS) Q1 2025 Earnings Call Transcript",
      "id": 134324382,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "VTRS",
      "source": "SeekingAlpha",
      "summary": "Viatris Inc. (NASDAQ:VTRS) Q1 2025 Earnings Conference Call May 8, 2025 8:30 AM ETCompany ParticipantsBill Szablewski - Head of Capital MarketsScott Smith -...",
      "url": "https://finnhub.io/api/news?id=55259bb63b342c62860292110a494b186b9bb506f91a6992fc3d67840ce8d4c8"
    }
  },
  {
    "ts": null,
    "headline": "Viatris Announces Positive Top-Line Results from Two Pivotal Phase 3 Studies of Novel Fast-Acting Meloxicam (MR-107A-02) for the Treatment of Moderate-to-Severe Acute Pain",
    "summary": "Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced positive results from its Phase 3 program of the novel fast-acting formulation of meloxicam (MR-107A-02) for the treatment of moderate-to-severe acute pain. The Phase 3 program consisted of two randomized, double-blind, placebo-(double-dummy) and active-controlled trials – one following herniorrhaphy surgery (NCT06215859) and one following bunionectomy surgery (NCT06215820). Both trials evaluated the efficacy and safety of",
    "url": "https://finnhub.io/api/news?id=3ff9fc1598d4f6fc5fbfbe9d92029dc4fad8c01a15b0ad75648a646b3bbaaec2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746700200,
      "headline": "Viatris Announces Positive Top-Line Results from Two Pivotal Phase 3 Studies of Novel Fast-Acting Meloxicam (MR-107A-02) for the Treatment of Moderate-to-Severe Acute Pain",
      "id": 134325660,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VTRS",
      "source": "Yahoo",
      "summary": "Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced positive results from its Phase 3 program of the novel fast-acting formulation of meloxicam (MR-107A-02) for the treatment of moderate-to-severe acute pain. The Phase 3 program consisted of two randomized, double-blind, placebo-(double-dummy) and active-controlled trials – one following herniorrhaphy surgery (NCT06215859) and one following bunionectomy surgery (NCT06215820). Both trials evaluated the efficacy and safety of",
      "url": "https://finnhub.io/api/news?id=3ff9fc1598d4f6fc5fbfbe9d92029dc4fad8c01a15b0ad75648a646b3bbaaec2"
    }
  },
  {
    "ts": null,
    "headline": "Viatris Inc. 2025 Q1 - Results - Earnings Call Presentation",
    "summary": "The following slide deck was published by Viatris Inc.",
    "url": "https://finnhub.io/api/news?id=4b2a1651083ab791c4a5d08514982fba64be3e5ac07b84c539b35b7ec20f2037",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746692641,
      "headline": "Viatris Inc. 2025 Q1 - Results - Earnings Call Presentation",
      "id": 134322813,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "VTRS",
      "source": "SeekingAlpha",
      "summary": "The following slide deck was published by Viatris Inc.",
      "url": "https://finnhub.io/api/news?id=4b2a1651083ab791c4a5d08514982fba64be3e5ac07b84c539b35b7ec20f2037"
    }
  },
  {
    "ts": null,
    "headline": "Viagra-maker Viatris beats quarterly estimates on demand for branded drugs in China",
    "summary": "Drugmaker Viatris beat WallStreet estimates for first-quarter profit and revenue onThursday, helped by sales of its branded drugs in China. The company's shares, which rose over 4% in...",
    "url": "https://finnhub.io/api/news?id=7bdd4c6322fa0f735ed3858803ca75bd2fcc5f630348fabcabaf83bdd0f5d698",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746692292,
      "headline": "Viagra-maker Viatris beats quarterly estimates on demand for branded drugs in China",
      "id": 134322666,
      "image": "",
      "related": "VTRS",
      "source": "Finnhub",
      "summary": "Drugmaker Viatris beat WallStreet estimates for first-quarter profit and revenue onThursday, helped by sales of its branded drugs in China. The company's shares, which rose over 4% in...",
      "url": "https://finnhub.io/api/news?id=7bdd4c6322fa0f735ed3858803ca75bd2fcc5f630348fabcabaf83bdd0f5d698"
    }
  },
  {
    "ts": null,
    "headline": "Viatris : VTRS Q1 2025 Earnings Infographic - FINAL",
    "summary": "Q1 2025 Financial Results Total Revenues $3.3B A...",
    "url": "https://finnhub.io/api/news?id=a15b0a8d35b85348d718b5fd5f24823a920047e5ef8a9352b1ae9a845d5bf59b",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746688031,
      "headline": "Viatris : VTRS Q1 2025 Earnings Infographic - FINAL",
      "id": 134321784,
      "image": "",
      "related": "VTRS",
      "source": "Finnhub",
      "summary": "Q1 2025 Financial Results Total Revenues $3.3B A...",
      "url": "https://finnhub.io/api/news?id=a15b0a8d35b85348d718b5fd5f24823a920047e5ef8a9352b1ae9a845d5bf59b"
    }
  },
  {
    "ts": null,
    "headline": "Viatris : VTRS Q1 2025 Non-GAAP Reconciliations - FINAL",
    "summary": "‌GAAP / Non-GAAP Reconciliations This document contains proprietary information of Viatris Inc. Unauthorized use, duplication, dissemination or disclosure to third...",
    "url": "https://finnhub.io/api/news?id=79158d2d3bb901e33fba9b61f969b65643716e6d4dde125ed94142a14d9ec5d5",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746688031,
      "headline": "Viatris : VTRS Q1 2025 Non-GAAP Reconciliations - FINAL",
      "id": 134321782,
      "image": "",
      "related": "VTRS",
      "source": "Finnhub",
      "summary": "‌GAAP / Non-GAAP Reconciliations This document contains proprietary information of Viatris Inc. Unauthorized use, duplication, dissemination or disclosure to third...",
      "url": "https://finnhub.io/api/news?id=79158d2d3bb901e33fba9b61f969b65643716e6d4dde125ed94142a14d9ec5d5"
    }
  },
  {
    "ts": null,
    "headline": "Viatris : Press Release (viatris reports first quarter 2025 results and reaffirms 2025)",
    "summary": "Viatris Reports First Quarter 2025 Results and Reaffirms 2025 Outlook May 8, 2025 Delivers Total Revenues in Line With...",
    "url": "https://finnhub.io/api/news?id=f3fd1af15f3edbf67dae619ff193c73b6e85666529b33a1ffca972e7db517c23",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746688031,
      "headline": "Viatris : Press Release (viatris reports first quarter 2025 results and reaffirms 2025)",
      "id": 134321781,
      "image": "",
      "related": "VTRS",
      "source": "Finnhub",
      "summary": "Viatris Reports First Quarter 2025 Results and Reaffirms 2025 Outlook May 8, 2025 Delivers Total Revenues in Line With...",
      "url": "https://finnhub.io/api/news?id=f3fd1af15f3edbf67dae619ff193c73b6e85666529b33a1ffca972e7db517c23"
    }
  },
  {
    "ts": null,
    "headline": "Viatris : VTRS Q1 2025 Earnings Presentation - FINAL",
    "summary": "Q1 2025 Earnings ...",
    "url": "https://finnhub.io/api/news?id=64a5c34986067ee70ab19da4f95ec292f3721bd4a6dd0de64d08b5f0253977cd",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746688031,
      "headline": "Viatris : VTRS Q1 2025 Earnings Presentation - FINAL",
      "id": 134321779,
      "image": "",
      "related": "VTRS",
      "source": "Finnhub",
      "summary": "Q1 2025 Earnings ...",
      "url": "https://finnhub.io/api/news?id=64a5c34986067ee70ab19da4f95ec292f3721bd4a6dd0de64d08b5f0253977cd"
    }
  },
  {
    "ts": null,
    "headline": "Viatris Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025",
    "summary": "Viatris Inc. reported earnings results for the first quarter ended March 31, 2025. For the first quarter, the company reported sales was USD 3,243.2 million compared to USD 3,653.5 million a year ago....",
    "url": "https://finnhub.io/api/news?id=7fe90277d6cfe74fee45c49e1407f8526b35c3987c42d21e3cda92f193eb521a",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746687540,
      "headline": "Viatris Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025",
      "id": 134323096,
      "image": "",
      "related": "VTRS",
      "source": "Finnhub",
      "summary": "Viatris Inc. reported earnings results for the first quarter ended March 31, 2025. For the first quarter, the company reported sales was USD 3,243.2 million compared to USD 3,653.5 million a year ago....",
      "url": "https://finnhub.io/api/news?id=7fe90277d6cfe74fee45c49e1407f8526b35c3987c42d21e3cda92f193eb521a"
    }
  },
  {
    "ts": null,
    "headline": "Viatris Inc. Reaffirms Earnings Guidance for the Fiscal Year 2025",
    "summary": "Viatris Inc. reaffirmed earnings guidance for the Fiscal Year 2025. For the year, company expected total Revenues to be in range of $13,500 -to $14,000 with mid point of $13,750....",
    "url": "https://finnhub.io/api/news?id=be7df0048374f13b6039632488a9ea44ae1db7ad4bbf53519ef61b1e21faa13a",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746687540,
      "headline": "Viatris Inc. Reaffirms Earnings Guidance for the Fiscal Year 2025",
      "id": 134322920,
      "image": "",
      "related": "VTRS",
      "source": "Finnhub",
      "summary": "Viatris Inc. reaffirmed earnings guidance for the Fiscal Year 2025. For the year, company expected total Revenues to be in range of $13,500 -to $14,000 with mid point of $13,750....",
      "url": "https://finnhub.io/api/news?id=be7df0048374f13b6039632488a9ea44ae1db7ad4bbf53519ef61b1e21faa13a"
    }
  },
  {
    "ts": null,
    "headline": "Viatris Announces Positive Results From Phase 3 Study Of Investigational Xulane Lo(TM) Low Dose Patch For Birth Control In Women Of Childbearing Potential",
    "summary": "Viatris Inc: * VIATRIS ANNOUNCES POSITIVE RESULTS FROM PHASE 3 STUDY OFINVESTIGATIONAL XULANE LO™ LOW DOSE PATCH FOR BIRTH CONTROL INWOMEN OF CHILDBEARING POTENTIAL *...",
    "url": "https://finnhub.io/api/news?id=598443efd5c37cd3e69cf244a451583fb2eac20165f26d1a8f21a1f84f993da9",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746687315,
      "headline": "Viatris Announces Positive Results From Phase 3 Study Of Investigational Xulane Lo(TM) Low Dose Patch For Birth Control In Women Of Childbearing Potential",
      "id": 134321560,
      "image": "",
      "related": "VTRS",
      "source": "Finnhub",
      "summary": "Viatris Inc: * VIATRIS ANNOUNCES POSITIVE RESULTS FROM PHASE 3 STUDY OFINVESTIGATIONAL XULANE LO™ LOW DOSE PATCH FOR BIRTH CONTROL INWOMEN OF CHILDBEARING POTENTIAL *...",
      "url": "https://finnhub.io/api/news?id=598443efd5c37cd3e69cf244a451583fb2eac20165f26d1a8f21a1f84f993da9"
    }
  },
  {
    "ts": null,
    "headline": "Viatris' pain drug meets main goals of two late-stage trials",
    "summary": "Viatris said on Thursday thatits fast-acting form of generic pain drug meloxicam met the maingoals of two late-stage studies. The company's shares rose 4.1% in premarket trading. ...",
    "url": "https://finnhub.io/api/news?id=290391f96ebe4c9157db50d565618ceb4fd792ec4b62e5112b0e24f4a1a1f368",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746687264,
      "headline": "Viatris' pain drug meets main goals of two late-stage trials",
      "id": 134321565,
      "image": "",
      "related": "VTRS",
      "source": "Finnhub",
      "summary": "Viatris said on Thursday thatits fast-acting form of generic pain drug meloxicam met the maingoals of two late-stage studies. The company's shares rose 4.1% in premarket trading. ...",
      "url": "https://finnhub.io/api/news?id=290391f96ebe4c9157db50d565618ceb4fd792ec4b62e5112b0e24f4a1a1f368"
    }
  },
  {
    "ts": null,
    "headline": "Viatris Announces Positive Top-Line Results from Two Pivotal Phase 3 Studies of Novel Fast-Acting Meloxicam (Mr-107A-02) for the Treatment of Moderate-To-Severe Acute Pain Pain",
    "summary": "Viatris Inc. announced positive results from its Phase 3 program of the novel fast-acting formulation of meloxicam for the treatment of moderate-to-severe acute pain. The Phase 3 program consisted of...",
    "url": "https://finnhub.io/api/news?id=20bfd61bd13bbb37f277b56638fbe91608473205dc30d24fc4eb98473f219e30",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746685800,
      "headline": "Viatris Announces Positive Top-Line Results from Two Pivotal Phase 3 Studies of Novel Fast-Acting Meloxicam (Mr-107A-02) for the Treatment of Moderate-To-Severe Acute Pain Pain",
      "id": 134322139,
      "image": "",
      "related": "VTRS",
      "source": "Finnhub",
      "summary": "Viatris Inc. announced positive results from its Phase 3 program of the novel fast-acting formulation of meloxicam for the treatment of moderate-to-severe acute pain. The Phase 3 program consisted of...",
      "url": "https://finnhub.io/api/news?id=20bfd61bd13bbb37f277b56638fbe91608473205dc30d24fc4eb98473f219e30"
    }
  },
  {
    "ts": null,
    "headline": "The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of June 3, 2025 in Viatris Inc. Lawsuit - VTRS",
    "summary": "NEW YORK, May 8, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Viatris Inc. . ...",
    "url": "https://finnhub.io/api/news?id=b7cf16e27a229e9130abbd5084ecaafe6554d23dcf2d65445f83728878194ded",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746683177,
      "headline": "The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of June 3, 2025 in Viatris Inc. Lawsuit - VTRS",
      "id": 134320772,
      "image": "",
      "related": "VTRS",
      "source": "Finnhub",
      "summary": "NEW YORK, May 8, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Viatris Inc. . ...",
      "url": "https://finnhub.io/api/news?id=b7cf16e27a229e9130abbd5084ecaafe6554d23dcf2d65445f83728878194ded"
    }
  }
]